| | | | |

Spread of Peritoneal Mesothelioma Slows with Apatinib

ByAlex Strauss
spread of peritoneal mesothelioma

An investigational drug called apatinib may help stop the growth and spread of peritoneal mesothelioma. Chinese researchers recently tested the VEGF inhibitor on mice infected with human mesothelioma. 

They found that the spread of peritoneal mesothelioma slowed way down in the presence of apatinib. The drug worked in the lab and in live mice with few serious side effects. If larger experiments confirm apatinib’s effectiveness, the next step could be trials in human mesothelioma patients. 

Apatinib Blocks Blood Vessel Formation

Apatinib is also known as Rivoceranib. It keeps cancer cells from using the protein VEGF. VEGF (vascular endothelial growth factor) allows tumors to spawn new blood vessels. A rich supply of fresh blood fuels the growth and spread of peritoneal mesothelioma. 

Apatinib is still experimental. A Chinese company is developing it for use against gastric cancers, metastatic breast cancer, and liver cancer. 

But some mesothelioma patients may also benefit. Peritoneal mesothelioma starts on the membrane that surrounds the abdominal organs. It accounts for about one in five cases of mesothelioma and is highly resistant to standard cancer treatments.

The liver and spleen are prime areas for the spread of peritoneal mesothelioma. If apatinib can prevent the spread of peritoneal mesothelioma to these and other critical organs, it could save lives. 

Blocking the Spread of Peritoneal Mesothelioma

The new tests on apatinib took place at Beijing Shijitan Hospital. Researchers tested the drug on mesothelioma cells in the lab. They also created a mouse model of mesothelioma using human cells. This allowed them to test apatinib’s impact on the spread of peritoneal mesothelioma. 

Researchers delivered apatinib directly into the stomachs of the sick mice using a technique called gastric gavage. Afterward, they measured how far the cancer spread in the abdomen. The amount of spread is the peritoneal cancer index (PCI). The lower the PCI, the better. 

“Our results showed that apatinib significantly inhibited the proliferation and migration of malignant peritoneal mesothelioma cells in vitro [in the lab] and induced cell cycle arrest,” writes study author Zhi-Ran Yang. 

Even more exciting was the fact that apatinib blocked the spread of peritoneal mesothelioma into the livers and spleens of mice. 

Tests of the treated mice showed that the drug also stimulated the immune system. It brought cancer-killing white blood cells to the area around the tumor. 

“We successfully established MPM PDX models and primary cell lines, and confirmed that apatinib effectively inhibited proliferation and metastasis of MPM in vitro and in vivo study,” writes Dr. Yang. 

The researchers say that apatinib “did not affect the function of important organs” or the body mass of the treated mice. 

Drug May Help with Pleural Disease, Too

In addition to slowing the spread of peritoneal mesothelioma, previous experiments suggest that apatinib may also help people with pleural mesothelioma. Pleural mesothelioma is more common than peritoneal mesothelioma. These tumors start on the membrane around the lungs. 

In 2018, apatinib kept a Chinese patient’s mesothelioma from growing for five months after two kinds of chemotherapy failed to stop it. Researchers suggested that apatinib could be an effective third-line treatment against chemo-resistant pleural mesothelioma. 

Sources:

Yang, ZR, et al, “Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo”, December 7, 2020, Frontiers in Oncology, eCollection, https://www.frontiersin.org/articles/10.3389/fonc.2020.585079/full

Du, S, et al, “Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report”, November 2018, Medicine (Baltimore), https://journals.lww.com/md-journal/Fulltext/2018/11090/Apatinib_for_salvage_treatment_of_advanced.46.aspx

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    ByAlex Strauss

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    ByAlex Strauss

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…